Erwin Coenen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Erwin Coenen has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Belén Valenzuela
Janssen‐Cilag Spain Part of Janssen Pharmaceutical Companies Madrid Spain
1 shared publication - Iolanda Cirillo
Janssen Clinical Pharmacology and Pharmacometrics Raritan New Jersey USA
1 shared publication Jay Ariyawansa
Janssen Statistical and Decision Sciences Raritan New Jersey USA
1 shared publication- Juan Jose Perez Ruixo
Johnson & Johnson Madrid Spain
1 shared publication - Oliver Ackaert
Johnson & Johnson Beerse Belgium
1 shared publication - Per Olsson Gisleskog
POG Pharmacometrics London UK
1 shared publication
Latest Publications
- Open Access
- 27 January 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (2) , e70114
Evaluation of the Effect of Loperamide on the Cardiac Repolarization Interval Using Exposure–Response Analysis
This analysis assessed the relationship between the plasma concentrations of loperamide and its N‐desmethyl loperamide meta‐ bolite (M1) and the potential QT interval prolongation at therapeutic and supratherapeutic doses. The exposure–response analysis was performed using the data from healthy adults participating in a randomized, double‐blind, single‐dose, four‐way (placebo; loperamide 8 mg [therapeutic]; loperamide 48 mg [supratherapeutic]; moxifloxacin 400 mg [positive control]) crossover study. The electrocardiographic measurements extracted from 12‐lead digital Holter recordings were time‐matched to pharmacokinetic sampling of loperamide/M1. The primary response variable was placebo‐adjusted change from baseline in Fridericia‐corrected QT interval (ΔΔQTcF); the exposure variable was loperamide and/or M1 concentration. A total of 53 participants with 1408 time‐matched pharmacokinetic and ΔΔQTcF measurements was analyzed. Hysteresis between both loperamide and M1 concentrations and ΔΔQTcF was observed with supratherapeutic dose. The pre‐specified linear concentration‐ΔΔQTcF relationship was driven by M1 concentrations in the effect compartment. The model‐predicted mean ΔΔQTcF at the geometric mean of the maximum concentration in the effect compartment was −0.526 msec (90% CI, −1.51 to 0.462) following 8‐mg dose (2.1 ng/mL) and 6.06 msec (90% CI, 3.86–8.27) following 48‐mg dose (14.2 ng/mL). The upper bound of two‐sided 90% CI was < 10 msec for both doses. The sensitivity analysis considering loperamide concentrations in the effect compartment instead of M1 as input for the concentration‐ΔΔQTcF analysis confirmed these findings. The data showed that loperamide or M1 does not have an effect on cardiac repolarization that exceeds the threshold of regulatory concern in healthy participants at doses of 8 and 48 mg.
- 27 January 2025
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (2) , e70114
Open AccessEvaluation of the Effect of Loperamide on the Cardiac Repolarization Interval Using Exposure–Response Analysis
This analysis assessed the relationship between the plasma concentrations of loperamide and its N‐desmethyl loperamide meta‐ bolite (M1) and the potential QT interval prolongation at therapeutic and supratherapeutic doses. The exposure–response analysis was performed using the data from healthy adults participating in a randomized, double‐blind, single‐dose, four‐way (placebo; loperamide 8 mg [therapeutic]; loperamide 48 mg [supratherapeutic]; moxifloxacin 400 mg [positive control]) crossover study. The electrocardiographic measurements extracted from 12‐lead digital Holter recordings were time‐matched to pharmacokinetic sampling of loperamide/M1. The primary response variable was placebo‐adjusted change from baseline in Fridericia‐corrected QT interval (ΔΔQTcF); the exposure variable was loperamide and/or M1 concentration. A total of 53 participants with 1408 time‐matched pharmacokinetic and ΔΔQTcF measurements was analyzed. Hysteresis between both loperamide and M1 concentrations and ΔΔQTcF was observed with supratherapeutic dose. The pre‐specified linear concentration‐ΔΔQTcF relationship was driven by M1 concentrations in the effect compartment. The model‐predicted mean ΔΔQTcF at the geometric mean of the maximum concentration in the effect compartment was −0.526 msec (90% CI, −1.51 to 0.462) following 8‐mg dose (2.1 ng/mL) and 6.06 msec (90% CI, 3.86–8.27) following 48‐mg dose (14.2 ng/mL). The upper bound of two‐sided 90% CI was < 10 msec for both doses. The sensitivity analysis considering loperamide concentrations in the effect compartment instead of M1 as input for the concentration‐ΔΔQTcF analysis confirmed these findings. The data showed that loperamide or M1 does not have an effect on cardiac repolarization that exceeds the threshold of regulatory concern in healthy participants at doses of 8 and 48 mg.